24/7 Market News Snapshot 11 September, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

September 11, 2025

DENVER, Colo., 11 September, 2025 (www.247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp. (NASDAQ:SLXN) is experiencing a significant surge, recently reaching $5.955 per share, reflecting a notable increase of 32.78% from a previous close of $4.485 in pre-market trading. This movement was fueled by the exchange of 11.81 million shares, underscoring robust investor interest in the company’s innovative therapeutic pipeline. Analysts perceive this jump as a signal of strong market confidence, reinforcing Silexion’s position in the realm of groundbreaking cancer therapies.

In conjunction with this market activity, Silexion has also announced a public offering of 1,500,000 ordinary shares, with associated series A and series B warrants to purchase equivalent shares. Priced at $4.00 per share, this capital raise is expected to generate gross proceeds of approximately $6.0 million, contingent upon standard closing conditions. The series A warrants, exercisable immediately, will enable investors to buy shares at the offering price and will remain valid for five years, while series B warrants will also permit purchases at $4.00 per share but will expire within twelve months.

The proceeds from this offering are slated to bolster Silexion’s pre-clinical studies and support general corporate strategies. The company is particularly focused on enhancing its lead product candidate aimed at addressing locally advanced pancreatic cancer as well as advancing its overall oncology portfolio. Promising results from a recent Phase 2a clinical trial suggest that Silexion’s first-generation product may offer considerable benefits compared to chemotherapy alone in treating KRAS mutations.

With a forward-looking strategy dedicated to developing therapies targeting KRAS-driven cancers, Silexion invites stakeholders and investors to stay engaged as it continues to innovate and expand its impact in the oncology space.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.